Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsHKSE:02561 7 Market Cap is HK$2,272.79 Mil as of Aug. 29, 2026. GuruFocus rates HKSE:02561 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 1,022 Drug Manufacturers companies, VISEN Pharmaceuticals ranks better than 52.64% on this metric.
VISEN Pharmaceuticals's quarterly market cap
declined
from Jun. 2025 (HK$4,757.45 Mil) to Dec. 2025 (HK$3,576.35 Mil) and
declined
from Dec. 2025 (HK$3,576.35 Mil) to Jun. 2026 (HK$2,272.78 Mil).
VISEN Pharmaceuticals's annual market cap
stayed the same
from Dec. 2023 (HK$0.00 Mil) to Dec. 2024 (HK$0.00 Mil) but then
increased
from Dec. 2024 (HK$0.00 Mil) to Dec. 2025 (HK$3,576.35 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. VISEN Pharmaceuticals's Enterprise Value for Today is HK$1,889.06 Mil.
VISEN Pharmaceuticals (HKSE:02561) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
VISEN Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (HKSE:02561) has a Market Cap of HK$2,272.79 Mil as of Aug. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on VISEN Pharmaceuticals and its competitors. According to the industry distribution chart, VISEN Pharmaceuticals ranks #484 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is VISEN Pharmaceuticals' Market Cap too high?
VISEN Pharmaceuticals' current Market Cap is HK$2,272.79 Mil. Based on the distribution chart, VISEN Pharmaceuticals ranks #484 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #484 out of 1022 companies for Market Cap. This puts VISEN Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 232.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 232.89, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 232.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current Market Cap is HK$2,272.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (HKSE:02561) has a current Market Cap of HK$2,272.79 Mil. The current Market Cap is HK$2,272.79 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For VISEN Pharmaceuticals (HKSE:02561), the current Market Cap is HK$2,272.79 Mil as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for HKSE:02561
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02561 has been successfully added to your 
